Search

Your search keyword '"Ossenkoppele, Gert"' showing total 730 results

Search Constraints

Start Over You searched for: Author "Ossenkoppele, Gert" Remove constraint Author: "Ossenkoppele, Gert" Publication Type Academic Journals Remove constraint Publication Type: Academic Journals
730 results on '"Ossenkoppele, Gert"'

Search Results

1. Midostaurin added to 10-day decitabine, for patients unfit for intensive chemotherapy with AML and higher risk MDS, irrespective of FLT3 mutational status, does not improve outcome

3. Rearrangements involving 11q23.3/KMT2A in adult AML: mutational landscape and prognostic implications – a HARMONY study

4. Bayesian interim analysis for prospective randomized studies: reanalysis of the acute myeloid leukemia HOVON 132 clinical trial

6. Age and sex associate with outcome in older AML and high risk MDS patients treated with 10-day decitabine

7. Bimodal expression of potential drug target CLL-1 (CLEC12A) on CD34+ blasts of AML patients.

8. Acute promyelocytic leukemia: long-term outcomes from the HARMONY project

10. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN

13. Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome

15. Safety and tolerability of AMG 330 in adults with relapsed/refractory AML: a phase 1a dose-escalation study.

20. Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trial

23. European Stop Tyrosine Kinase Inhibitor Trial (EURO-SKI) in Chronic Myeloid Leukemia: Final Analysis and Novel Prognostic Factors for Treatment-Free Remission.

24. EHA evaluation of the ESMO—Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for haematological malignancies

25. Safety and efficacy of talacotuzumab plus decitabine or decitabine alone in patients with acute myeloid leukemia not eligible for chemotherapy: results from a multicenter, randomized, phase 2/3 study

26. The EUTOS long-term survival (ELTS) score is superior to the Sokal score for predicting survival in chronic myeloid leukemia

27. Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations

36. Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party

38. CD34+CD38− leukemic stem cell frequency to predict outcome in acute myeloid leukemia

39. Therapeutic value of clofarabine in younger and middle-aged (18-65 years) adults with newly diagnosed AML

40. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel

41. Core outcome set measurement for future clinical trials in acute myeloid leukemia: the HARMONY study protocol using a multi-stakeholder consensus-based Delphi process and a final consensus meeting

48. Impact of age on efficacy and toxicity of nilotinib in patients with chronic myeloid leukemia in chronic phase: ENEST1st subanalysis

49. Prospective validation of the prognostic relevance of CD34+CD38– AML stem cell frequency in the HOVON-SAKK132 trial

Catalog

Books, media, physical & digital resources